CVKD Stock Forecast & Price Target

Cadrenal Therapeutics has entered a significant collaboration with Abbott to support the Phase 3 TECH-LVAD trial, which aims to assess the efficacy and safety of tecarfarin in patients with left ventricular assist devices, indicating robust potential for its drug candidate. Additionally, Cadrenal has successfully transitioned the manufacturing of tecarfarin's active pharmaceutical ingredient to a U.S.-based facility, enhancing its clinical and regulatory development capabilities and supply chain security. These strategic moves reflect confidence in tecarfarin’s potential to address unmet needs in anticoagulation therapy, positively influencing the company's growth outlook.

Cadrenal Therapeutics's financial outlook is hampered by a combination of failed or inconclusive clinical trials and the ongoing need for adequate funding to advance its drug candidate, tecarfarin. The company's reported earnings per share (EPS) for 1Q25 was at ($2.09), which, although better than estimates, still reflects significant losses that indicate underlying financial instability. Additionally, with only $7.3 million remaining in cash, the company faces a critical challenge in securing further financing to sustain operations and continue drug development.